Skip to main content

Psoriatic arthritis

Differences in Presentation and Outcomes of Early vs Late Onset PsA Dr. Petryna ( @DrPetryna) discusses abstract 0377 presented at #ACR22. Abstract 0377: Differences in Early-onset vs. Late-onset PsA: Data from the RESPONDIA and REGISPONSER Studies https://t.co/3dwYmx7Hva https://t.co/ZFlFmWRbMK
Best of #ACR22 Day 2 in PSA -Efficacy and Safety Results from BE OPTIMAL in PsA -JAK inhibitors in rheumatic diseases -Who is the Winner? Switch vs Cycle in PsA -Women vs. Men: Response to Treatment in Seronegative Arthritis and more.https://t.co/JSKafxioMT https://t.co/Ov0VuCdX5y
Topic Podcasts - PsA Part1 Best of PsA on Day 1 #ACR22https://t.co/uXxUwy6u9G https://t.co/GDDXgcn2EC
Are MDA criteria created equal in PsA? Dr. Rachel Tate ( @uptoTate ) reviews abstract #1496: Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA Criteria Are Met? Presented at #ACR22. https://t.co/H4wPHEV8D5 https://t.co/NqXYxXRNEX
pain

Pain in Psoriatic Arthritis

Nov 22, 2022

The prioritisation of pain, and its evaluation, is important in those with psoriatic arthritis, when the already incredibly heterogenous nature of the condition can complicate assessment. Whilst we lean towards all pain in PsA being nociceptive in nature, evidence suggests that a significant

Read Article
Differences in Presentation and Outcomes of Early vs Late Onset PsA Dr. Petryna ( @DrPetryna) discusses abstract 0377 presented at #ACR22. Abstract 0377: Differences in Early-onset vs. Late-onset PsA: Data from the RESPONDIA and REGISPONSER Studies https://t.co/Bw3RHp3lSR https://t.co/Yva84Iw8hk
Patient Reported Outcomes in PsA Using Novel IL 17A Inhibitor Dr. Sims ( @DrCassySims) discusses abstract 0199 presented at #ACR22.https://t.co/L14WoimRE6 https://t.co/LhgyE1LwGa
Sleep asleep

Sleep Quality & Psoriatic Arthritis

Nov 15, 2022

For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many. Psoriatic arthritis is associated with a number of sleep problems, including trouble falling and staying asleep, poor-quality sleep and feeling sleepy during the day. Clinical

Read Article
Best of

ACR Best Abstracts - Day 3

Nov 14, 2022

The last day was jammed with important reports and research including the late breaking abstracts. 



 

Read Article
pills-384846_640%20%281%29.jpg

The complexity of opioid use in spondyloarthritis

Nov 14, 2022

A few things we know about opioids: use is common; it’s not efficacious in the treatment of spondyloarthritis; and, there is an opioid epidemic and its users are stigmatized. Abstract 0402 is a retrospective study that looked at patients with psoriatic arthritis or ankylosing spondylitis in the

Read Article
Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commerically-insured patients. 20-44%! of new prescriptions not filled by 6 months. Higher for csDMARDs than b/tsDMARDs @RheumNow #ACR22 Abstr#2199 https://t.co/Pwg6GKu7Gg https://t.co/wPF0pu1UDa
Pain in #psoriaticarthritis might not be all inflammatory.. In this study presented by Dr F Sunzini: 👉PsA pts w/⬆️FM scores had⬆️functional brain connectivity bet mid-post IC & thalamus, phgyrus & PFC ..so consider nociplastic pain too & adjust mgt #ACR22 @RheumNow ABST#2256 https://t.co/suCAvx0pD5
BE OPTIMAL Study - Bimekizumab (IL-17A and IL-17F inhibitor) for treatment of PsA. Similar ACR 50 (~50%) response rates of Bimekizumab, adalimumab, and placebo (switched to BKZ at wk 16). ~60% PASI100 in BKZ #ACRBest Abs#L02 @RheumNow #ACR22 https://t.co/W2B2kyju9F
Ritchlin et al. Bimekizumab in bDMARD naive PsA. 52 week results. Not surprisingly, week 16 outcomes sustained. No joint difference to ADA, skin slightly better @RheumNow #ACR22 Abstr#L02 https://t.co/RjCV8Hb3HR https://t.co/a0NQFyFZlt
A new murine model to study Pso and PsA! Immunodeficient mice NSG-SGM3 🐁 injected w/ serum & PBMCs from Pso and/or PsA pts = pro & arthritis (same phenotype than pts) Mice skin & synovia >effector memory CD8 T cell & < naïvehttps://t.co/cxSvEZC9LyAbs#L04 #ACR22 @Rheumnow https://t.co/hfbtSsP3f8
#L02 #acr22 @rheumnow Bimekizumab ph3 in PsA: meaningful clinical improvement, improved mTSS, no new safety signals. Wk 52 ACR50: 53.0% PBO/BKZ, 54.5% BKZ, 50.0% ADA; MDA 53.7% PBO/BKZ, 55.0% BKZ, 52.9% ADA . mTSS change from baseline ≤0.5): 87.3% PBO/BKZ, 89.3% BKZ, 94.1% ADA https://t.co/NYRrPUBjt1
BE OPTIMAL: BKZ in PsA Phase 3 RCT Data at 52 wks 700+ completed study ACR50: 53% PBO/BKZ, 54% BKZ, 50% ADA PASI 100 65% PBO/BKZ, 61% BKZ, 48% ADA No Rx progression 87% PBO/BKZ, 89% BKZ, 94% ADA Candida infections 7% BKZ, 0.7% ADAhttps://t.co/MMjN1Aa3qfAbs#L02 #ACR22 @Rheumnow https://t.co/keF0QOZMwA
Get the skinny on Bimmy! Gotta learn this name #Bimekizumab in bio naive PsA N=852 Bimmy=IL17 A & F inhibitor Great data on skin & joints. Where will it fit in as we have other IL17Ai’s is IL17F giving added value? #ACR22 #ACRBest @RheumNow https://t.co/wNAzTaLhsM
male female

Do different genders experience PsA differently?

Nov 14, 2022

There has been a lot of talk lately about the difference in the way male and female PsA patients experience their disease.  Are the differences only cultural or are there important clinical differences in the disease presentation, organ involvement and complications that physicians should be

Read Article
Does tofacitinib work better in patients with PsA and AS who smoke? Abstract #1036 #ACR22 @RheumNow 🚬519 ever smokers 🚭767 never smokers 💉In PsA only, TOF efficacy was greater in ever smokers vs. PBO ✋Overall, efficacy was generally comparable in ever v. never 🚬
Here's the 1 year model #ACR22 @RheumNow https://t.co/VhEuJMMyIt
Eder et al. New PRESTO prediction model for PsA development in PsO. 1 year and 5 year models presented @RheumNow #ACR22 Abstr#1612 https://t.co/xMMVaIGnN5 https://t.co/RlJ3ZlEeDE
syringe,needle,vaccine

Vaccine Efficacy in Patients with Seronegative Spondyloarthritis

Nov 14, 2022

Vaccine efficacy remains an important and highly discussed topic at this year’s annual meeting given the ongoing COVID-19 global health crisis, current influenza season, and recently published 2022 ACR guidelines for vaccinations in patients with rheumatic and musculoskeletal diseases.

Read Article
FitzGerald et al. PsA patients with higher levels of IL-23-IL-17 pathway biomarkers more likely to benefit from TYK2i deucravacitinib @RheumNow #ACR22 Abstr#2133 https://t.co/eVq4XQgX5l https://t.co/HZlTS5OZ2s
Fleischmann et al. Safety of TYK2i Deucravacitinib in PsA/PsO in terms of labs. Really no effect on lab values other than increase in trigs. Guess this is why they don't have lab monitoring on label? @RheumNow #ACR22 Abstr#2132 https://t.co/ueIVKQc6jr https://t.co/u99QE71VQ5
×